8V5A
Prefusion-stabilized Respirovirus type 3 Fusion protein
This is a non-PDB format compatible entry.
Summary for 8V5A
| Entry DOI | 10.2210/pdb8v5a/pdb |
| EMDB information | 42981 |
| Descriptor | Fusion glycoprotein F0, Camelid nanobody 4C06 (2 entities in total) |
| Functional Keywords | fusion protein, viral glycoprotein, membrane fusion, viral protein, viral protein-immune system complex, viral protein/immune system |
| Biological source | Human respirovirus 3 More |
| Total number of polymer chains | 6 |
| Total formula weight | 199907.12 |
| Authors | |
| Primary citation | Langedijk, J.P.M.,Cox, F.,Johnson, N.V.,van Overveld, D.,Le, L.,van den Hoogen, W.,Voorzaat, R.,Zahn, R.,van der Fits, L.,Juraszek, J.,McLellan, J.S.,Bakkers, M.J.G. Universal paramyxovirus vaccine design by stabilizing regions involved in structural transformation of the fusion protein. Nat Commun, 15:4629-4629, 2024 Cited by PubMed Abstract: The Paramyxoviridae family encompasses medically significant RNA viruses, including human respiroviruses 1 and 3 (RV1, RV3), and zoonotic pathogens like Nipah virus (NiV). RV3, previously known as parainfluenza type 3, for which no vaccines or antivirals have been approved, causes respiratory tract infections in vulnerable populations. The RV3 fusion (F) protein is inherently metastable and will likely require prefusion (preF) stabilization for vaccine effectiveness. Here we used structure-based design to stabilize regions involved in structural transformation to generate a preF protein vaccine antigen with high expression and stability, and which, by stabilizing the coiled-coil stem region, does not require a heterologous trimerization domain. The preF candidate induces strong neutralizing antibody responses in both female naïve and pre-exposed mice and provides protection in a cotton rat challenge model (female). Despite the evolutionary distance of paramyxovirus F proteins, their structural transformation and local regions of instability are conserved, which allows successful transfer of stabilizing substitutions to the distant preF proteins of RV1 and NiV. This work presents a successful vaccine antigen design for RV3 and provides a toolbox for future paramyxovirus vaccine design and pandemic preparedness. PubMed: 38821950DOI: 10.1038/s41467-024-48059-w PDB entries with the same primary citation |
| Experimental method | ELECTRON MICROSCOPY (3 Å) |
Structure validation
Download full validation report
